In addition, IHC staining of Ki67, a proliferation marker, was dramatically decreased after WK369 administration compared to controls (Figure 6C), these data underline that WK369 achieves superior anti-ovarian cancer effects in vivo. This evidence concerns the gene MKI67 and ovarian carcinoma.